Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04273217 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers
A Phase 1 study, sponsored by AbViro.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT04273217 is a Phase 1 study that has completed, run by AbViro. The registered enrollment target is 42 participants.
The verdict
NCT04273217, a Phase 1 study, has completed, sponsored by AbViro.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
AV-1 is a human monoclonal antibody (mAb) being investigated as a potential therapy for dengue, a mosquito-borne viral disease with extensive global public health impact. Globally, over 2 billion people are thought to be at risk of infection from the dengue virus and there are an estimated 390 million infections each year. Current treatment options for dengue are limited to supportive care, so a safe and effective treatment would provide substantial public health benefits. AV-1 has not previously been tested in humans. This study aims to determine the safety of AV-1 in healthy adult volunteers, when administered as a single IV infusion. The results of the study are based on the clinical study report and statistical analysis plan.
Interventions
- DRUG Placebo
- DRUG AV-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-02-04 |
| Est. Completion | 2021-07-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04273217
The ClinicalTrials.gov registry entry for NCT04273217 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbViro, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04273217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04273217 about?
NCT04273217 is a clinical study titled "A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers". AV-1 is a human monoclonal antibody (mAb) being investigated as a potential therapy for dengue, a mosquito-borne viral disease with extensive global public health impact. Globally, over 2 billion people are thought to be at risk of infection from the dengue virus and there are an estimated 390 milli...
What is the current status of trial NCT04273217?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2020-02-04. Estimated completion is 2021-07-08.
What interventions are being tested in trial NCT04273217?
The interventions under investigation include: Placebo (DRUG), AV-1 (DRUG).
Who is sponsoring clinical trial NCT04273217?
This trial is sponsored by AbViro, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.